BRPI0716495A2 - (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos. - Google Patents
(r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos.Info
- Publication number
- BRPI0716495A2 BRPI0716495A2 BRPI0716495-5A2A BRPI0716495A BRPI0716495A2 BR PI0716495 A2 BRPI0716495 A2 BR PI0716495A2 BR PI0716495 A BRPI0716495 A BR PI0716495A BR PI0716495 A2 BRPI0716495 A2 BR PI0716495A2
- Authority
- BR
- Brazil
- Prior art keywords
- phenoterol
- pharmaceutical composition
- analogue
- compounds
- preparation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 1
- 229960001022 fenoterol Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83716106P | 2006-08-10 | 2006-08-10 | |
| US92782507P | 2007-05-03 | 2007-05-03 | |
| PCT/US2007/075731 WO2008022038A1 (en) | 2006-08-10 | 2007-08-10 | Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0716495A2 true BRPI0716495A2 (pt) | 2014-03-04 |
Family
ID=38917814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0716495-5A2A BRPI0716495A2 (pt) | 2006-08-10 | 2007-08-10 | (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos. |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US20100168245A1 (pt) |
| EP (1) | EP2064174B1 (pt) |
| JP (2) | JP5302194B2 (pt) |
| KR (1) | KR101378067B1 (pt) |
| CN (1) | CN103739503A (pt) |
| AU (1) | AU2007286051B2 (pt) |
| BR (1) | BRPI0716495A2 (pt) |
| CA (1) | CA2660707C (pt) |
| IL (1) | IL196965A (pt) |
| MX (1) | MX2009001534A (pt) |
| WO (1) | WO2008022038A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008022038A1 (en) | 2006-08-10 | 2008-02-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure |
| PE20091156A1 (es) * | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
| CN101531602B (zh) * | 2008-03-10 | 2014-08-27 | 北京德众万全医药科技有限公司 | 一种hplc法分析分离酒石酸福莫特罗中间体的方法 |
| EP2544677A4 (en) * | 2010-03-08 | 2013-07-10 | Univ Tennessee Res Foundation | BETA-ADRENERGE RECEPTOR AGONISTS AND USES THEREOF |
| AU2011224241B2 (en) * | 2010-03-10 | 2014-05-08 | Sri International | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas |
| JO3192B1 (ar) * | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| WO2013177418A1 (en) | 2012-05-25 | 2013-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of regulating cannabinoid receptor activity-related disorders and diseases |
| US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| WO2017059268A1 (en) * | 2015-10-01 | 2017-04-06 | Mitchell Woods Pharmaceuticals, Inc. | Methods of reducing chemoresistance and treating cancer |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| KR101987841B1 (ko) | 2019-03-13 | 2019-06-11 | 김도현 | 완구총 |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| CN110376313B (zh) * | 2019-08-20 | 2022-06-07 | 广州健康元呼吸药物工程技术有限公司 | 一种检测富马酸福莫特罗或其相关制剂中杂质的方法 |
| EP4146183A4 (en) * | 2020-05-05 | 2024-05-29 | Irving W. Wainer | METHOD OF TREATING VIRAL INFECTION SYMPTOMS |
| JP2023530679A (ja) * | 2020-06-11 | 2023-07-19 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | フェノテロール臭化水素酸塩、β２アドレナリン受容体アゴニスト、及びその誘導体を用いて近視を予防及び治療するための方法及び組成物 |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL296701A (pt) * | ||||
| AT235270B (de) | 1962-08-18 | 1964-08-25 | Chemie Linz Ag | Verfahren zur Herstellung von N-substituierten Phenyläthanolaminderivaten und deren Salzen |
| NL300751A (pt) | 1962-11-30 | 1900-01-01 | ||
| SE354279B (pt) * | 1969-06-13 | 1973-03-05 | Draco Ab | |
| CH564509A5 (pt) * | 1969-12-12 | 1975-07-31 | Boehringer Sohn Ingelheim | |
| DE1962497C3 (de) * | 1969-12-12 | 1979-09-20 | C.H. Boehringer Sohn, 6507 Ingelheim | Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel |
| DE2010883A1 (de) * | 1970-03-07 | 1971-09-23 | Troponwerke Dinklage & Co, 5000 Köln-Mülheim | Pharmakologisch wirksame Aminoalkohole und Verfahren zu ihrer Darstellung |
| AT308139B (de) * | 1970-07-27 | 1973-06-25 | Degussa | Verfahren zur Herstellung von neuen basisch substituierten Alkyltheophyllinen, ihren Isomeren und Säureadditionssalzen |
| IT1044214B (it) * | 1971-04-22 | 1980-03-20 | Zambeletti Spa L | 2 idrossi 2 feniletilamine so stituite dotate di proprieta vasoattive e processo per la loro preparazione |
| JPS532194A (en) | 1976-06-25 | 1978-01-10 | Sekisui Jushi Kk | Packing method by plastic band |
| WO1992001477A1 (en) * | 1990-07-26 | 1992-02-06 | G.D. Searle & Co. | Polymeric drug delivery system |
| US6299863B1 (en) * | 1992-04-03 | 2001-10-09 | Sepracor Inc. | Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy |
| US5795564A (en) | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| GB9107196D0 (en) * | 1991-04-05 | 1991-05-22 | Sandoz Ag | Improvements in or relating to organic compounds |
| US6866839B2 (en) * | 1991-04-05 | 2005-03-15 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| WO1998001099A2 (en) | 1996-07-05 | 1998-01-15 | E.C. Pesterfield Assoc., Inc. | Method of treating retinal ischemia and glaucoma |
| US6015837A (en) * | 1996-08-29 | 2000-01-18 | New York Medical College | Method for treating scoliosis with β2-adrenoceptor agonists |
| AU9672598A (en) | 1997-09-30 | 1999-04-23 | E.C. Pesterfield Associates, Inc. | Galenic forms of r-or rr-isomers of adrenergic beta-2 agonists |
| ZA994264B (en) * | 1998-07-01 | 2000-01-25 | Warner Lambert Co | Stereoisomers with high affinity for adrenergic receptors. |
| AU6167599A (en) | 1998-09-30 | 2000-04-17 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Use of a beta2 adrenergic receptor agonist in the treatment of cardiovascular disease |
| ES2296923T3 (es) * | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| WO2003099764A1 (en) * | 2002-05-28 | 2003-12-04 | Theravance, Inc. | ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS |
| US20050107417A1 (en) * | 2003-07-28 | 2005-05-19 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising a novel anticholinergic and a betamimetic |
| ATE407925T1 (de) | 2003-11-03 | 2008-09-15 | Myogen Inc | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen |
| JP2007530566A (ja) * | 2004-03-22 | 2007-11-01 | ミオゲン インコーポレイティッド | （ｒ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用 |
| EP1781331A1 (en) | 2004-08-09 | 2007-05-09 | Université Catholique de Louvain | Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases |
| NZ556335A (en) * | 2005-01-11 | 2009-07-31 | Glaxo Group Ltd | Cinnamate salts of a beta-2 adrenergic agonist |
| WO2008022038A1 (en) * | 2006-08-10 | 2008-02-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure |
-
2007
- 2007-08-10 WO PCT/US2007/075731 patent/WO2008022038A1/en not_active Ceased
- 2007-08-10 AU AU2007286051A patent/AU2007286051B2/en active Active
- 2007-08-10 EP EP07813996.1A patent/EP2064174B1/en active Active
- 2007-08-10 US US12/376,945 patent/US20100168245A1/en not_active Abandoned
- 2007-08-10 MX MX2009001534A patent/MX2009001534A/es active IP Right Grant
- 2007-08-10 JP JP2009524015A patent/JP5302194B2/ja active Active
- 2007-08-10 CA CA2660707A patent/CA2660707C/en active Active
- 2007-08-10 KR KR1020097002634A patent/KR101378067B1/ko active Active
- 2007-08-10 BR BRPI0716495-5A2A patent/BRPI0716495A2/pt not_active IP Right Cessation
- 2007-08-10 CN CN201310705914.3A patent/CN103739503A/zh active Pending
-
2009
- 2009-02-09 IL IL196965A patent/IL196965A/en active IP Right Grant
-
2011
- 2011-12-21 US US13/333,866 patent/US8703826B2/en active Active
-
2013
- 2013-06-20 JP JP2013129406A patent/JP2013224316A/ja active Pending
-
2014
- 2014-03-06 US US14/199,208 patent/US9522871B2/en active Active
-
2016
- 2016-11-09 US US15/347,354 patent/US9908841B2/en active Active
-
2018
- 2018-01-18 US US15/874,747 patent/US10308591B2/en active Active
-
2019
- 2019-04-22 US US16/390,982 patent/US10562843B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008022038A1 (en) | 2008-02-21 |
| CN103739503A (zh) | 2014-04-23 |
| KR20090051171A (ko) | 2009-05-21 |
| US9908841B2 (en) | 2018-03-06 |
| JP2013224316A (ja) | 2013-10-31 |
| JP2010500381A (ja) | 2010-01-07 |
| EP2064174B1 (en) | 2016-10-26 |
| US9522871B2 (en) | 2016-12-20 |
| KR101378067B1 (ko) | 2014-04-10 |
| CA2660707C (en) | 2014-07-08 |
| US20170081276A1 (en) | 2017-03-23 |
| MX2009001534A (es) | 2009-04-08 |
| IL196965A0 (en) | 2009-11-18 |
| US20140187645A1 (en) | 2014-07-03 |
| US20120157543A1 (en) | 2012-06-21 |
| US10562843B2 (en) | 2020-02-18 |
| US20160009636A9 (en) | 2016-01-14 |
| AU2007286051B2 (en) | 2013-01-10 |
| IL196965A (en) | 2015-10-29 |
| US20100168245A1 (en) | 2010-07-01 |
| US20180141894A1 (en) | 2018-05-24 |
| CA2660707A1 (en) | 2008-02-21 |
| EP2064174A1 (en) | 2009-06-03 |
| US20190248732A1 (en) | 2019-08-15 |
| AU2007286051A1 (en) | 2008-02-21 |
| US10308591B2 (en) | 2019-06-04 |
| JP5302194B2 (ja) | 2013-10-02 |
| US8703826B2 (en) | 2014-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0716495A2 (pt) | (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos. | |
| BRPI0614205A2 (pt) | composto, composição farmacêutica, e, uso de composto | |
| BRPI0618904A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| BRPI0720124A2 (pt) | Composições farmacêuticas e seus métodos de uso. | |
| BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
| BRPI0609802A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| CL2007002377A1 (es) | Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno. | |
| BRPI0716171A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto. | |
| BRPI0922435A2 (pt) | "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso." | |
| BRPI0815190A2 (pt) | Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo | |
| HUS1400051I1 (hu) | Lurazidont tartalmazó gyógyászati készítmény | |
| BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
| BRPI0717699A2 (pt) | "composição e seus processos de preparação, uso de uma composição e uso coméstico de uma composição! | |
| BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BRPI0811865A2 (pt) | Derivados heterocíclicos pirrolo-nitrogenados, a preparação e o uso farmacêutico dos mesmos | |
| BRPI0818804A2 (pt) | Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. | |
| BRPI0922233A2 (pt) | compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas. | |
| CL2007002376A1 (es) | Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas. | |
| BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
| CL2007003645A1 (es) | Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria. | |
| BRPI0716698A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| BRPI0907892A2 (pt) | Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo | |
| BRPI0813587A2 (pt) | Composto, uso do mesmo, e, composição farmacêutica | |
| CL2007002619A1 (es) | Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion. | |
| BRPI0810399A2 (pt) | Composto, composição farmacêutica que o contém e uso do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |